Trial results

$SEPN — SEP-479

Septerna, Inc. (SEPN) SEP-479: trial results in Hypoparathyroidism, 2027.

Research by Catalyst Intel

The catalyst

"As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027."

— Septerna, Inc., 10-Q filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

SEPN-SEP479-2026

Company

Septerna, Inc.

Kind

Trial results

Indication

Hypoparathyroidism

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.